Learn More
In order to evaluate the antiproliferative effects of recombinant human interferon-gamma 2c (rHu IFN-gamma 2c), recombinant human interferon-gamma (rHu IFN-gamma), natural interferon-beta (IFN-beta), and their combination with cytotoxic agents, 17 different human bladder carcinoma cell lines were tested in vitro. The antiproliferative effects were compared(More)
Eight patients with superficial bladder cancer were treated by systemic interferon (IFN) alpha-2 application to investigate whether the rate of local tumor recurrence could be diminished. All patients had recurrent high-grade urothelial cancer. Recombinant human IFN alpha-2 was administered by daily intramuscular injections for a period of 6 weeks. The(More)
In previous investigations, it was demonstrated that interferons (IFN) have antiproliferative effects in human urothelial carcinomas. However, appreciable differences were found in the sensitivity of the individual tumors investigated. We therefore examined whether this might be due to a different receptor status of the cells. The IFN-sensitive cell lines(More)
In order to evaluate whether the 2,5-oligo-A synthetase (OAS) is a reliable marker for monitoring a systemic interferon treatment 7 patients suffering from recurrent superficial carcinoma of the bladder and 4 patients with metastatic renal cell carcinoma were monitored during systemic interferon (IFN) treatment. Throughout the study, human recombinant IFN(More)
We analysed the bacteriological urinary findings of all inpatients of the urological department on admission, during hospitalization and on discharge, over a period of one year. The percentage of urological patients with florid urinary tract infections was less than 10%. The most commonly found pathogen was E. coli, followed by Proteus, enterococci,(More)
The treatment of metastatic renal carcinoma is still unsatisfactory because of the lack of effective systemic therapy. In 14 patients with metastatic renal carcinoma an attempt was made to influence the course of the disease by administration of recombinant human interferon (rHu-IFN) gamma; 9 patients were evaluated after treatment. There was partial(More)
Natural killer (NK) cell stimulation can be repeatedly elicited by cyclic administration of recombinant human interferon (rHu IFN) gamma in patients with metastatic renal cell cancer. In all cycles of treatment, the elevation of the cytolytic activity of the NK cells was statistically significant. The shift of the T4/T8 ratio (T-helper/T-suppressor(More)